title: [Clinical observation of abdominal regional fluorouracil implants in advanced gastric cancer patients during operation].
abstract: OBJECTIVE
  To investigate the postoperative adverse events and survival of patients with sustained-released fluorouracil implanted during operation.
  
  
  METHODS
  Data of 124 patients with advanced gastric cancer undergoing radical operation in Tianjin Medical University Cancer Institute and Hospital from January 2007 to January 2009 were analyzed retrospectively. All the patients were divided into two groups according to whether intra-operative fluorouracil was implanted or not. The treatment group(n=64) was implanted with fluorouracil in abdominal cavity after radical resection. The control group(n=60) did not receive fluorouracil implant in abdominal cavity after radical resection. Abdominal drainage fluid, temperature and adverse events within 15 postoperative days and 3-year survival were observed and compared between the two groups.
  
  
  RESULTS
  Pathological findings of the two groups were similar. No statistical significances existed in abdominal drainage fluid, temperature and adverse events within 15 postoperative days(P>0.05). The 3-year survival rate was higher in treatment group(64.3% vs. 42.4%, P=0.018).
  
  
  CONCLUSIONS
  Intra-operative sustained-released fluorouracil implants are safe and tolerable, and can improve the survival rate of patients with advanced gastric cancer.
authors: Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. tjlianghan@126.com.
authors: Hongmin
authors: H
authors: Liu
authors: Jingli
authors: J
authors: Cui
authors: Nan
authors: N
authors: Jiang
authors: Jingyu
authors: J
authors: Deng
authors: Xiaona
authors: X
authors: Wang
authors: Liangliang
authors: L
authors: Wu
authors: Han
authors: H
authors: Liang
mesh_terms: D034841:Abdominal Cavity; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil